Tyra Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Tyra Biosciences, Inc. (TYRA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $10.23M, a 60.38% increase year-over-year.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.85M, a 22.19% increase year-over-year.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.58M, a 0.05% increase year-over-year.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.38M, a 44.64% increase year-over-year.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $28.01M, a 22.83% increase from fiscal 2024.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.80M, a 68.58% increase from fiscal 2023.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.53M, a 27.74% increase from fiscal 2022.
- Tyra Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.59M, a 266.75% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.23M 10-Q · filed 2026-08-04 | $18.08M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $7.85M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $28.01M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $7.58M 10-Q · filed 2025-11-05 | $13.96M derived: sum of 2 quarters · filed 2026-08-04 | $20.38M derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $6.38M 10-Q · filed 2026-08-04 | $12.80M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $6.42M 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $22.80M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $7.57M 10-Q · filed 2025-11-05 | $11.98M derived: sum of 2 quarters · filed 2025-11-05 | $16.10M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $4.41M 10-Q · filed 2025-11-05 | $8.53M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $4.12M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $13.53M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $4.38M 10-Q · filed 2024-11-07 | $6.91M derived: sum of 2 quarters · filed 2024-11-07 | $9.34M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.53M 10-Q · filed 2024-11-07 | $4.96M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.43M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $10.59M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $1.02M 10-Q · filed 2023-11-07 | $3.71M derived: sum of 2 quarters · filed 2023-11-07 | $7.68M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.69M 10-Q · filed 2023-11-07 | $6.66M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $3.97M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $2.89M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $507.00K 10-Q · filed 2022-11-03 | $845.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.02M derived: sum of 3 quarters · filed 2022-11-03 | $1.15M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $338.00K 10-Q · filed 2022-11-03 | $512.00K derived: sum of 2 quarters · filed 2022-11-03 | $639.00K derived: sum of 3 quarters · filed 2022-11-03 | $745.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | $174.00K 10-Q · filed 2022-11-03 | $301.00K derived: sum of 2 quarters · filed 2022-11-03 | $407.00K derived: sum of 3 quarters · filed 2022-11-03 | $505.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | $127.00K 10-Q · filed 2021-11-03 | $233.00K derived: sum of 2 quarters · filed 2021-11-03 | $331.00K derived: sum of 3 quarters · filed 2021-11-03 | $439.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $106.00K 10-Q · filed 2021-11-03 | $204.00K derived: sum of 2 quarters · filed 2021-11-03 | $312.00K derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $98.00K 10-Q · filed 2021-11-03 | $206.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $108.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |